Citigroup Inc Increases Eli Lilly and Co (LLY) Price Target to $100.00
Eli Lilly and Co (NYSE:LLY) had its target price increased by analysts at Citigroup Inc from $92.00 to $100.00 in a report released on Wednesday. The brokerage presently has a “buy” rating on the stock. Citigroup Inc’s price target suggests a potential upside of 22.04% from the company’s previous close.
Other equities analysts also recently issued research reports about the company. Goldman Sachs Group Inc reaffirmed a “buy” rating and issued a $85.00 target price (up previously from $82.00) on shares of Eli Lilly and in a research report on Wednesday, December 21st. Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $86.00 target price on the stock in a research report on Tuesday, January 24th. Jefferies Group LLC reaffirmed a “buy” rating on shares of Eli Lilly and in a research report on Friday, February 17th. Barclays PLC upped their target price on Eli Lilly and from $80.00 to $85.00 and gave the company a “buy” rating in a research report on Wednesday, February 1st. Finally, Credit Suisse Group AG reaffirmed a “buy” rating on shares of Eli Lilly and in a research report on Tuesday, March 21st. Two research analysts have rated the stock with a sell rating, four have given a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $88.70.
Eli Lilly and (NYSE:LLY) opened at 81.94 on Wednesday. The firm has a market cap of $86.11 billion, a price-to-earnings ratio of 31.76 and a beta of 0.30. Eli Lilly and has a one year low of $64.18 and a one year high of $86.72. The stock’s 50 day moving average price is $84.25 and its 200-day moving average price is $77.93.
Eli Lilly and (NYSE:LLY) last posted its earnings results on Tuesday, January 31st. The company reported $0.95 EPS for the quarter, missing the consensus estimate of $0.98 by $0.03. Eli Lilly and had a net margin of 12.90% and a return on equity of 24.74%. The firm earned $5.76 billion during the quarter, compared to analyst estimates of $5.54 billion. During the same period in the previous year, the company posted $0.78 EPS. Eli Lilly and’s revenue for the quarter was up 7.2% compared to the same quarter last year. Analysts forecast that Eli Lilly and will post $4.11 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This story was reported by Watch List News and is the property of of Watch List News. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.watchlistnews.com/eli-lilly-and-co-lly-stock-rating-reaffirmed-by-citigroup-inc-2/1203368.html.
In other Eli Lilly and news, EVP Derica W. Rice sold 11,162 shares of the company’s stock in a transaction on Friday, February 3rd. The stock was sold at an average price of $77.14, for a total transaction of $861,036.68. Following the completion of the sale, the executive vice president now directly owns 58,443 shares in the company, valued at $4,508,293.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the company’s stock in a transaction on Thursday, March 30th. The stock was sold at an average price of $84.67, for a total value of $17,780,700.00. Following the sale, the insider now owns 124,690,804 shares of the company’s stock, valued at $10,557,570,374.68. The disclosure for this sale can be found here. Insiders have sold 688,162 shares of company stock valued at $55,440,777 over the last 90 days. Corporate insiders own 0.20% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in LLY. First Command Financial Services Inc. boosted its stake in Eli Lilly and by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock valued at $103,000 after buying an additional 84 shares during the last quarter. Integrated Wealth Management boosted its stake in Eli Lilly and by 3.7% in the third quarter. Integrated Wealth Management now owns 1,389 shares of the company’s stock valued at $112,000 after buying an additional 50 shares during the last quarter. Financial Architects Inc boosted its stake in Eli Lilly and by 4.5% in the third quarter. Financial Architects Inc now owns 1,423 shares of the company’s stock valued at $114,000 after buying an additional 61 shares during the last quarter. Tarbox Group Inc. boosted its stake in Eli Lilly and by 0.7% in the third quarter. Tarbox Group Inc. now owns 1,539 shares of the company’s stock valued at $124,000 after buying an additional 11 shares during the last quarter. Finally, LeJeune Puetz Investment Counsel LLC acquired a new stake in Eli Lilly and during the fourth quarter valued at $136,000. Hedge funds and other institutional investors own 75.15% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co and related companies with Analyst Ratings Network's FREE daily email newsletter.